The Mounjaro Dose Ladder: what to expect at each step.

Before we climb

This guide is for anyone in India standing at the foot of that ladder — either holding their first KwikPen or trying to decide whether the cost and commitment are worth it. We'll walk through each step with the kind of specifics that abstract dosage charts skip: what the appetite suppression actually feels like, how much weight people typically lose per month at each dose, which side effects show up where, what each pen costs in May 2026, and — critically — where most people should stop.

A few honest framings before we begin. Variance is the rule, not the exception. Two people of the same age, weight, and starting BMI can have completely different experiences at 5 mg. The numbers in this article are ranges drawn from clinical trial data (the SURMOUNT and SURPASS programmes), community-observed patterns from Indian and global GLP-1 patient communities, and the patterns Indian endocrinologists report seeing in clinic. Treat them as terrain, not as a map.

Second, the harder parts will be named honestly. There is a real pattern of emotional flattening at the top of the ladder that the marketing literature does not discuss. There is also a strong tendency among new patients to assume "higher dose = better outcome." This is one of the most expensive misconceptions in GLP-1 care.

Third, by the end of this article you should hold four ideas: most people find their home dose at 5 or 7.5 mg; 10 mg is often the peak, not a midpoint; 12.5 and 15 mg have real quality-of-life cost; and the right climb is personal, not protocol.

If any of the terms below are new — golden dose, food noise, NSV, suppression, sulphur burps — our GLP-1 Dictionary covers all of them.

The ladder at a glance

These are community-observed patterns and clinical trial averages, not individual guarantees. Variance is significant — some people lose more on 5 mg than others do on 15 mg.

2.5 mg — The loading dose

Clinical purpose

The 2.5 mg dose is not a therapeutic dose. Eli Lilly designed it to let your GIP and GLP-1 receptors adjust to tirzepatide gradually, so that the gastrointestinal side effects at 5 mg and above are tolerable. Indian endocrinologists treat the first four weeks as orientation: you are not really being treated for obesity yet, you are being prepared for treatment. (Still finding a doctor to supervise titration? Any MBBS-registered doctor can prescribe — our guide compares endo vs GP vs online.)

Suppression character

Appetite suppression on 2.5 mg is partial and delayed. Most people feel nothing on day one or day two. By the start of the second week, food noise begins to quieten — you notice you are less interested in your usual evening snack, portions at meals shrink without conscious effort, and the constant low-grade thinking-about-food settles down. Roughly one in five users feels essentially nothing for the full four weeks. This does not predict non-response at higher doses; many "nothing happened on 2.5 mg" users see strong suppression on 5 mg.

Weight loss range

A typical month-one loss on 2.5 mg is 3–5 kg for an average responder, 5–8 kg for high responders (often higher starting weights with significant water shedding), and 0–2 kg for slow responders. Anyone losing more than 8 kg in month one is almost certainly losing a lot of water and glycogen, not just fat.

Side effects

Mild nausea in the first 24–48 hours after the first shot is near-universal — most users describe it as "queasy on a moving bus" rather than vomiting. Mild fatigue is common in the first three days. Constipation begins to emerge by week two. A minority experience a racing heart or jittery feeling, often tied to a sudden drop in blood sugar from reduced food intake — eating something with protein and complex carbs usually resolves it. Sulphur burps (the rotten-egg-tasting eructations that catch new users off guard) are mild or absent at this dose for most people.

Cost in India (May 2026)

The Mounjaro KwikPen 2.5 mg has an Indian MRP of ₹13,125 per month across major online pharmacies. PharmEasy and Tata 1mg list it at this price; Apollo Pharmacy stocks it for the same MRP; MrMed and Medkart occasionally undercut by 5–10% with promotional discounts. This compares to an original Eli Lilly launch MRP of ₹14,000 per pen reported by Reuters and Business Standard on 13 August 2025 — pharmacy MRPs have settled slightly below the launch price.

What to prepare for

First-shot anxiety is universal — even people comfortable with insulin syringes find the KwikPen procedure unfamiliar. The drug becomes easier on weeks two and three. Trust the four-week minimum even if you feel nothing for the first two weeks. Many users who later become strong responders had a quiet first month.

5 mg — The first therapeutic dose

Clinical purpose

The 5 mg dose is the first one Lilly designed for sustained therapeutic effect. In SURMOUNT-1, the pivotal obesity trial published in The New England Journal of Medicine (Jastreboff et al., 2022), participants on 5 mg achieved a 16.0% average body weight reduction over 72 weeks. This is the dose where the drug actually starts doing the work it was approved for.

Suppression character

Suppression becomes substantially stronger. Food noise quietens in a way that surprises people — many describe forgetting to eat lunch, finishing half a plate and feeling done, or losing interest in foods they used to crave. There is a recognised community pattern of the "5 mg long pause" — patients who lose 6–10 kg on 5 mg, then plateau, then are tempted to climb. For many, holding at 5 mg for three to five months produces better total weight loss than rushing to 7.5 mg.

Weight loss range

A typical month on 5 mg yields 3–4 kg for average responders, 4–6 kg for high responders, and 1–2 kg for slow responders. Loss tends to be more linear and predictable than at 2.5 mg, because the water-shedding phase is mostly behind you.

Side effects

This is where sulphur burps emerge in earnest — the distinctive rotten-egg taste caused by hydrogen sulphide build-up as tirzepatide slows gastric emptying. Acid reflux is common, especially after evening meals. Fatigue on dose-day (typically the 24 hours after injection) becomes a recognisable pattern. Constipation often peaks here. A minority continue to experience anxiety or a racing heart, particularly if they are not eating enough. In the SURMOUNT-1 safety data, nausea was reported in 24.6% of participants on 5 mg, 33.7% on 10 mg, and 31.0% on 15 mg — confirming that the GI burden does not simply increase linearly with dose.

For Indian users, sulphur burps deserve a specific warning: high-sulphur foods that are staples in the Indian diet — eggs, garlic, onions, dals (especially when cooked with hing), brassicas like cabbage and cauliflower, and rich non-vegetarian curries — will reliably worsen the burps. This is not a reason to eliminate these foods. It is a reason to know that a Sunday lunch of mutton biryani may extract a price on Monday morning.

Cost in India (May 2026)

Mounjaro KwikPen 5 mg MRP is ₹16,406 per month, listed at this price on PharmEasy, Tata 1mg, and Apollo Pharmacy. MrMed and Netmeds typically run promotional discounts of 8–12%, bringing it down to roughly ₹14,800–₹15,200.

"I forgot lunch existed for the first time in my adult life on 5 mg." — community-reported pattern, Indian GLP-1 patient forums

This is where the drug "really works" for most people, and where the cost-benefit feels clearest. Sulphur burps catch nearly everyone by surprise. The 5 mg dose being manageable rather than overwhelming is normal — if it is overwhelming, that usually signals you need more time at this dose, not a step up.

7.5 mg — The committed phase

Clinical purpose

7.5 mg is the next step when weight loss on 5 mg has slowed below the rate you and your clinician planned for. SURMOUNT-1 did not test 7.5 mg as a maintenance dose — it is technically a titration step toward 10 mg — but in real-world Indian practice, many patients stop here and stay. (When you reach the dose you'll hold, the same careful logic applies in reverse — here's how to come off Mounjaro without regaining, and the lowest dose that protects your result.) Mumbai-based obesity-medicine teams describe weeks 13–16 at 10 mg as "the best-tolerated effective dose" for the majority of patients, with many holding at 7.5 mg or 10 mg as their final maintenance dose.

Suppression character

This is where most people describe the drug as having "really kicked in." Genuine hunger becomes rare. Food preferences shift — heavy, oily, or rich meals become unappealing in a way that is hard to fake. Patients report that street food they used to crave now seems too much, that mithai tastes cloyingly sweet, that two rotis is suddenly enough.

Weight loss range

Typical 7.5 mg monthly loss is 3–5 kg average, 5–6 kg for high responders, and 2–3 kg for those approaching goal weight (loss slows as you get leaner — this is biology, not the drug failing).

Side effects

If you handled 5 mg, 7.5 mg is usually a manageable step. Sulphur burps may flare for one to two weeks after the dose increase, then settle. Bowel habits become unpredictable for some — alternating loose stools and constipation. Fatigue becomes more pronounced and starts to extend beyond dose-day. Sleep disruption begins for a minority — typically waking at 3 or 4 a.m. and struggling to return to sleep. Mild emotional flatness is reported by perhaps one in ten users — a sense that things feel a bit muted, but not yet distressing.

Cost in India (May 2026)

Mounjaro KwikPen 7.5 mg MRP is ₹20,625 per month. This is the first major price jump on the ladder — ₹4,200 more than 5 mg per month, or about ₹50,000 more across a year. PharmEasy currently lists it at ₹18,150 after a 12% promotional discount. Availability has been inconsistent at this strength through early 2026 — both Tata 1mg and Apollo Pharmacy have reported intermittent stockouts of the 7.5 mg pen specifically, while 5 mg and 10 mg remain reliably stocked. The pricing structure is notable: at original launch in August 2025, Eli Lilly priced 7.5 mg and 10 mg identically at ₹22,000, a structure that pharmacies have preserved at the current ₹20,625 level.

What to prepare for

Many Indian patients describe 7.5 mg as the "sustainable working" dose — strong enough that the drug is clearly doing its job, gentle enough that life is not organised around side effects. If you are losing well, sleeping well, and the side effects are manageable, this is a legitimate long-term home. The instinct to push to 10 mg "just to see" is often a financial mistake.

10 mg — The peak for many

Clinical purpose

10 mg is the maximum useful intensity for a large share of patients. In SURMOUNT-1, participants on 10 mg lost an average of 21.4% of body weight over 72 weeks — almost as much as the 22.5% on 15 mg, despite being two-thirds the dose. The marginal gain from 10 → 15 mg is small; the side effect cost is not.

Suppression character

This is where the community language shifts from "less hungry" to something more absolute. Patients describe the experience as the word hunger being erased from their internal vocabulary — they no longer recognise the physical signal of needing to eat. Many find themselves having to set reminders to eat. Cravings are essentially absent. Food becomes utilitarian: fuel, not pleasure.

Weight loss range

4–6 kg per month for average responders is common — often the highest sustained monthly rate of the entire journey. High responders see 6–8 kg per month; those approaching goal weight see 3–4 kg as loss naturally slows.

Side effects

Fatigue tends to become consistent rather than dose-day-only. Sleep disruption affects perhaps a quarter of users at this dose. Emotional flattening — distinct from depression but recognisable — begins for a meaningful minority. Hair shedding (telogen effluvium, triggered by rapid weight loss rather than the drug directly) typically peaks at this dose, two to four months after the metabolic stress begins. The SURMOUNT-1 safety data showed alopecia in 5.7% of participants on tirzepatide 15 mg versus 1.0% on placebo, with rates rising steadily with dose — the highest incidence in those losing the most weight fastest. Muscle loss risk becomes significant if protein intake is not deliberately maintained.

Cost in India (May 2026)

Mounjaro KwikPen 10 mg MRP is ₹20,625 per month — identical to 7.5 mg. This is one of the most important practical facts on the ladder: the move from 7.5 to 10 mg costs you nothing extra. MrMed has historically offered competitive pricing on the 10 mg KwikPen with discounts bringing it closer to ₹17,500–₹18,500 during promotions; PharmEasy lists around ₹18,150 with current discount; Apollo Pharmacy holds at full MRP.

Why 10 mg is the plateau (and why staying here is often the right call)

There is a well-documented community pattern of patients reaching 10 mg, losing well, and then choosing not to climb further — even when their doctor presents 12.5 mg as the next step. The reasoning, when you unpack it, is sound.

For a typical Indian patient starting at 80–110 kg, by the time they reach 10 mg:

• Appetite suppression is already complete — there is no additional suppression to gain
• Receptor saturation effects mean the marginal benefit of additional drug is small
• Side effects scale faster than weight loss — fatigue, sleep, emotional flatness, hair shedding
• Indian obesity-medicine practitioners increasingly endorse the lowest effective dose principle — the goal is the lowest dose that delivers meaningful, sustained weight loss, not the maximum possible dose
• The biology of weight loss naturally slows as you approach a healthier BMI — pushing more drug at a system that is already responding rarely improves the outcome

The lowest effective dose principle — use the lowest dose that achieves your clinical goal — applies here with unusual force. The instinct to "max out" because the next pen exists is a common, expensive error.

"The word hunger has been erased from my dictionary." — community-reported pattern, GLP-1 patient experience descriptions

A question that often emerges at 10 mg is: Why am I not enjoying anything anymore? Food has gone neutral. Social eating feels performative. The pleasure of a long meal with family is muted. This is real, and worth naming aloud with your clinician before deciding whether to step up. Equally, protein becomes critical at this dose — many patients find themselves comfortably eating only 800–1,000 calories a day, which is too low for muscle preservation. A minimum of 1.2–1.6 g of protein per kg of target body weight is the floor most obesity-medicine clinicians recommend.

If you are losing well on 10 mg, sleeping reasonably, eating enough protein, and your blood work is clean, 10 mg is often the right dose to plan the rest of your strategy from — not a midpoint to rush past.

12.5 mg — Diminishing returns

Clinical purpose

12.5 mg exists for genuine non-responders to 10 mg, for patients with very high starting weights (130+ kg) who need more aggressive titration, and for diabetes patients whose HbA1c is not at target despite 10 mg. It is not a default next step.

Suppression character

The additional suppression from 12.5 mg over 10 mg is often imperceptibly small. The qualitative change patients describe is different — not "less hungry" but numb. Food enjoyment can disappear entirely. Several community patterns surface at this dose that are rare lower down: patients skipping doses occasionally "just to feel something," patients describing meals as transactional, patients noting that the texture of a favourite food no longer registers.

Weight loss range

2–4 kg per month average, 1–2 kg for slow responders. A common tapering curve at this dose looks like: 3 kg in month one, 3.5 kg in month two, 1.5 kg in month three. The drug is still working — the body is just closer to its set point and biology is resisting further loss.

Side effects

Anhedonia (the inability to feel pleasure) becomes a real concern in a minority — perhaps 5–10% of users at this dose report a recognisable version of it. Sleep disruption intensifies. Hair shedding can worsen, particularly if calorie intake has dropped below maintenance needs. Loose skin becomes more apparent as fat loss outpaces skin remodelling. Muscle loss risk is significant — at this dose, many patients eat below the threshold needed to preserve lean mass even with deliberate protein intake.

Cost in India (May 2026)

Mounjaro KwikPen 12.5 mg MRP is ₹25,781 per month — a ₹5,156 jump over 10 mg, or about ₹62,000 per year for marginal additional benefit. Pens at this strength are less widely stocked: Tata 1mg and PharmEasy carry them but with longer fulfilment windows; Apollo Pharmacy stocks reliably; smaller local chemists often do not stock 12.5 mg at all and require an order ahead.

15 mg — The ceiling

Clinical purpose

15 mg is the maximum approved dose of tirzepatide. It is indicated for patients with very high starting weights, with diabetes plus obesity needing aggressive glycaemic control, or with documented strong non-response at lower doses. SURMOUNT-1 showed 22.5% average weight loss at this dose over 72 weeks — only 1.1 percentage points more than 10 mg.

Suppression character

Marginal additional suppression versus 12.5 mg. Food becomes entirely transactional for most users at this dose. A minority report stronger emotional flattening, low motivation that bleeds into work and relationships, and mild depressive symptoms.

Weight loss range

1–3 kg per month is the common range. Many patients on 15 mg are in the final 5–10 kg before their goal weight, where biology naturally slows the loss curve regardless of dose.

Side effects

Every side effect of 12.5 mg, more pronounced. Emotional flatness, sleep disruption, and persistent fatigue are the three most common reasons patients step back down — and stepping back down to 10 mg or 7.5 mg almost always restores quality of life within four to six weeks without significant weight regain, provided behaviour and protein intake are maintained.

Cost in India (May 2026)

Mounjaro KwikPen 15 mg MRP is ₹25,781 per month — same as 12.5 mg. Availability has been intermittent through 2025 and into 2026; both PharmEasy and Tata 1mg list the pen but with frequent "out of stock" windows. Apollo Pharmacy and MrMed have been the more reliable channels for 15 mg.

What to prepare for

15 mg is rarely the right destination. Most patients who reach goal weight do so at 7.5 or 10 mg. 15 mg is often a step taken and quickly stepped back from — a final push toward a stuck endpoint, then a return to a sustainable maintenance dose. If you find yourself at 15 mg, the question is rarely "should I go higher?" (you cannot) but "is this still serving me?" — and the honest answer at six months is often no.

Budgeting the climb

The cost of a full Mounjaro journey in India depends heavily on how fast you climb and how high you go.

The fast-titration journey. A patient who titrates one step every four weeks, reaches 15 mg, holds for six months, then tapers spends roughly 12 months on medication. Drug cost: approximately ₹2,20,000–₹2,80,000 depending on time spent at each step. Add consultations, baseline and follow-up labs (HbA1c, lipid profile, thyroid, kidney function), and supplements (protein powder, multivitamin, sometimes biotin for shedding): ₹15,000–₹25,000. Total 12-month spend: roughly ₹2,35,000–₹3,05,000.

The 5 mg long-pause journey. A patient who spends one month at 2.5 mg, four to six months at 5 mg, two to three months at 7.5 mg, then moves to a maintenance strategy spends substantially less. Twelve months of medication: roughly ₹1,50,000–₹1,90,000. Plus extras: ₹1,65,000–₹2,15,000 total.

The difference — roughly ₹70,000 to ₹1,00,000 over a year — is the real cost of climbing higher than you needed to. For many Indian patients, that money is better spent on a personal trainer, a dietitian, and a maintenance plan than on the marginal additional weight loss from 12.5 or 15 mg.

Hidden savings worth knowing

The biggest unlock in 2026 is the generic semaglutide wave. After the Indian semaglutide patent expired on 20 March 2026, multiple manufacturers entered Day 1 with branded generics — Sun Pharma's Noveltreat (~₹3,400/month), Dr. Reddy's Obeda (~₹4,200/month), Alkem's Semasize (~₹1,800/month), Natco's Semanat (~₹1,290/month for vial form), and others. For maintenance — that is, holding your weight after reaching goal — switching from Mounjaro to a generic semaglutide is a dramatic cost reduction. Against the Mounjaro 10 mg MRP of ₹20,625/month, a Natco vial at ₹1,290/month is roughly a 94% reduction; even pen-device generics in the ₹4,000–₹4,500/month range deliver 78–81% savings. This is a conversation worth having with your endocrinologist well before you reach your goal weight, because the transition takes planning. See our detailed Mounjaro-to-semaglutide switch guide.

Local chemists in metros frequently beat online pharmacy MRPs by ₹500–₹1,500 per month on KwikPens, particularly for the 5 mg and 10 mg strengths where volumes are highest — though cold-chain quality must be verified before buying off the shelf. Credit card stacking on PharmEasy and Tata 1mg can realistically yield 25–33% effective discounts during quarterly health sale events. Our pharmacy-by-pharmacy buying guide walks through the trade-offs.

Why the 10 mg plateau is okay — often, the right place to stop

A specific pattern deserves its own section because it is so common and so frequently second-guessed: Indian patients who start in the 80–115 kg range often find that 10 mg is not a midpoint but a ceiling.

The math works like this. Appetite suppression on 10 mg is essentially complete for the majority of users — there is no more food noise to silence. Weight loss continues, but is being driven by the caloric deficit the suppression has already created, not by anything additional 12.5 or 15 mg would add. Receptor pharmacology is also working against you: by 10 mg, the dual GIP/GLP-1 receptors are heavily occupied, and additional drug produces diminishing physiological effect.

The biology of weight loss also slows naturally as you approach a healthier BMI. Your body becomes more efficient, metabolic rate falls, and the simple thermodynamic deficit shrinks. Pushing more tirzepatide at this slowing curve rarely accelerates it — the limiting factor has shifted from appetite to physics.

For patients in the 80–115 kg starting range, this means 10 mg typically delivers a caloric deficit sufficient to reach goal weight, appetite suppression that holds through the maintenance phase, a side effect profile that remains within tolerable limits, and a cost (₹20,625/month) that is identical to 7.5 mg and roughly 80% of the higher doses. If you are losing well on 10 mg, sleeping reasonably, eating adequate protein, and your suppression is reliable, the clinical case for pushing higher is thin.

This is not advice to refuse a dose increase your endocrinologist recommends for a specific clinical reason. It is a corrective to the common assumption that more drug equals more progress.

The non-responder caveat

A small but real subset of patients — perhaps 5–10% — experience a different pattern: strong appetite suppression and weight loss for the first four weeks at 2.5 mg, then a sudden loss of effect by week five or six. Titration upward through 5, 7.5, and 10 mg never fully restores the early suppression. Many end up at 15 mg with weight loss that is moderate at best and clearly behaviour-driven rather than drug-driven.

The clinical path for genuine non-responders looks something like this. First, comprehensive bloodwork — HbA1c, full thyroid panel including TSH and free T4, morning cortisol, sex hormone panel (low testosterone in men and PCOS-pattern androgens in women are common confounders — see our PCOS guide and thyroid guide), iron studies, and vitamin D. Second, an audit of concurrent medications that may blunt weight loss — insulin, sulphonylureas, pioglitazone, certain antidepressants, steroids, beta-blockers. Third, an honest conversation about switching molecules — tirzepatide non-responders sometimes respond to semaglutide, and vice versa. Finally, accepting that for some patients, GLP-1 medication provides moderate help and the rest of the work must be behavioural. This is not failure; it is information.

A final note on the climb

The Mounjaro ladder is built like a fitness machine — it lets you add intensity. Most users do not need maximum intensity. The right question at every step is not "can I go higher?" but "is this dose still working?" If it is, stay. If it has stopped working, look at protein intake, sleep, stress, and behaviour before reaching for the next pen. The lowest effective dose is not a compromise. For the majority of patients, it is the destination.